Ignite Creation Date:
2025-12-24 @ 6:37 PM
Ignite Modification Date:
2025-12-29 @ 2:29 AM
Study NCT ID:
NCT05957757
Status:
RECRUITING
Last Update Posted:
2023-08-31
First Post:
2023-05-12
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression
Sponsor:
RenJi Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-08-05
Start Date Type:
ACTUAL
Primary Completion Date:
2026-06-08
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-06-08
Completion Date Type:
ESTIMATED
First Submit Date:
2023-05-12
First Submit QC Date:
None
Study First Post Date:
2023-07-24
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-08-29
Last Update Post Date:
2023-08-31
Last Update Post Date Type:
ACTUAL